+37%

est. 2Y upside i

HealthcareSeries D+

Rank

#2327

Sector

Healthcare Services

Est. Liquidity

~0Y

Data Quality

Data: High

NephroPlus, now a publicly traded company, presents a strong upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (40%)+100%

NephroPlus significantly expands its international footprint, particularly in high-revenue markets like Saudi Arabia, and further consolidates the fragmented Indian market. This drives revenue to over $180M by FY28 with sustained 35%+ growth and strong margin expansion, justifying a market capitalization exceeding $1.3B.

Base (35%)+20%

NephroPlus maintains its leadership in the organized Indian dialysis market and achieves steady, albeit slower, international expansion. Revenue grows at a consistent 20-25% YoY, reaching approximately $130M by FY28, leading to a modest increase in market capitalization to around $800M.

Bear (25%)-40%

Increased regulatory pressures or changes in government reimbursement schemes in India, coupled with slower-than-expected international growth and intensified competition, lead to margin compression and decelerated revenue growth. This could result in a market capitalization decline to approximately $400M.

Est. time to liquidity~0.0 years

Preference Stack Risk

severe

Funding Intensity

31%

Investors hold approximately $205M in liquidation preferences ahead of common shareholders.

Dilution Risk

low

As a publicly traded company, significant dilution from future private funding rounds is unlikely.

Secondary Liquidity

active

Shares are actively traded on the NSE, providing immediate liquidity for equity holders.

View all 3 open roles at NephroPlus →

Last updated: February 18, 2026

Questions to Ask at the Interview

Strategic questions based on NephroPlus's data — designed to show you've done your homework.

  • 1

    “Given NephroPlus's strong international expansion, particularly the high revenue potential in markets like Saudi Arabia, how is the company prioritizing and managing the unique regulatory and operational challenges in these diverse geographies?”

  • 2

    “NephroPlus has demonstrated impressive revenue growth and margin expansion in its recent Q3 FY26 results. What are the key strategic initiatives and operational efficiencies the company is focusing on to sustain this growth trajectory and further enhance profitability over the next two years?”

  • 3

    “As a publicly listed company, what is the company's philosophy regarding employee equity, and how does it plan to ensure that common stock holders continue to see meaningful upside given the historical preference stack from prior funding rounds?”

Community

Valuation Sentiment

Our model estimates +37% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.